Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Return on Equity (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Return on Equity for 11 consecutive years, with 0.11% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 3.0% to 0.11% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.11% through Dec 2025, up 3.0% year-over-year, with the annual reading at 0.69% for FY2025, 3.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.11% at Marker Therapeutics, up from 0.38% in the prior quarter.
  • The five-year high for Return on Equity was 0.38% in Q4 2023, with the low at 1.05% in Q2 2022.
  • Average Return on Equity over 5 years is 0.38%, with a median of 0.41% recorded in 2023.
  • The sharpest move saw Return on Equity surged 128bps in 2023, then crashed -65bps in 2024.
  • Over 5 years, Return on Equity stood at 0.82% in 2021, then grew by 9bps to 0.75% in 2022, then soared by 150bps to 0.38% in 2023, then plummeted by -137bps to 0.14% in 2024, then grew by 20bps to 0.11% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.11%, 0.38%, and 0.46% for Q4 2025, Q3 2025, and Q2 2025 respectively.